Résztvevőt keres itt: Chile3. fázis
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A legfontosabb adatok
- Ki végzi
- Incyte Corporation
- Hol
- Santiago és Valdivia (Chile)Mind a 3 helyszín megnézéseMég 20 másik országban, 304 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 600 fő, tervezett
- Kezdés
- 2025. febr. 28.
- Várható befejezés
- 2028. febr. 28.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- povorcitinib
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults who finished treatment in an earlier Incyte trial of povorcitinib and were helped by it. They will keep taking povorcitinib.
- Életkor
- 18 Years and older
- Nem
- All sexes can join.
- A betegség stádiuma
- People who took part in an earlier povorcitinib trial for hidradenitis suppurativa, prurigo nodularis or vitiligo.
- Korábbi kezelés
- Must have completed the treatment period of an earlier Incyte povorcitinib trial without safety or tolerability problems, and had benefit from the drug, as judged by the study doctor. Cannot join after a biologic immunomodulator (such as adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab) or a live, attenuated vaccine within the 28 days before starting.
A részvétel fő kizáró okai
- Povorcitinib was stopped for good during the earlier trial.
- Povorcitinib was paused for safety or efficacy reasons at or after the last visit of the earlier trial.
- Plans to get a live, attenuated vaccine during the study or within 8 weeks after the last dose.
- Pregnant, planning pregnancy, or breastfeeding.
- Known allergy or severe reaction to povorcitinib, its ingredients, or similar drugs.
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Ability to comprehend and willingness to sign a written ICF for the study
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements
- Willingness to avoid pregnancy or fathering children as defined in the protocol
- Willingness and ability to comply with the study Protocol and procedures
Ki nem vehet részt
- Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:; Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab); Live, attenuated vaccine
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
- Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class
- Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; Other protocol-defined Inclusion/Exclusion Criteria may apply
- Had been permanently discontinued from study treatment during the parent study
- Women who are pregnant (or who are considering pregnancy) or breastfeeding
Helyszínek itt: Chile
Még 20 másik országban, 304 helyszínen
- SantiagoHospital not named in the registryRésztvevőt keres
- SantiagoHospital not named in the registryRésztvevőt keres
- ValdiviaHospital not named in the registryRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
A vizsgálat csoportja
- povorcitinibA vizsgált kezelés
Participants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 13.